Clinical Trial Update: CD19 and CD22 Targeted CAR-T Cell Therapy for Relapsed/Refractory B Cell Leukemia and Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial updating CAR-T therapy targeting CD19 and CD22 for relapsed/refractory B-cell leukemia and lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Leukemia
• B-cell Lymphoma

Drugs mentioned

• CD19 and CD22 targeted CAR-T cell therapy

Snippet

Sponsor: Chongqing Precision Biotech Co., Ltd | Conditions: Leukemia, B-cell, Lymphoma, B-Cell | Phase 1, Phase 2 | Status: UNKNOWN